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Abstract
Background: Pneumococcal conjugate vaccine strategies in GAVI-eligible countries are focusing on infant
immunization but this strategy may not be optimal in all settings. We aimed to collect all available population
based data on pneumococcal meningitis throughout life in the African meningitis belt and then to model overall
meningitis risk to help inform vaccine policy.
Methods: After a systematic review of literature published from 1970 through the present, we found robust
population-based Streptococcus pneumoniae (Sp) meningitis data across age strata for four African meningitis belt
countries that included 35 surveillance years spanning from 1970 to 2005. Using these data we modeled disease
risk for a hypothetical cohort of 100,000 persons followed throughout life.
Results: Similar to meningococcal meningitis, laboratory-confirmed pneumococcal meningitis was seasonal,
occurring primarily in the dry season. The mean annual Sp meningitis incidence rates were 98, 7.8 to 14, and 5.8 to
12 per 100,000 among persons <1, 1 through 19, and 20 to 99 years of age, respectively, which (in the absence of
major epidemics) were higher than meningococcal meningitis incidences for persons less than 1 and over 20 years
of age. Mean Sp meningitis case fatality ratios (CFR) among hospitalized patients ranged from 36-66% depending
on the age group, with CFR exceeding 60% for all age groups beyond 40 years; depending on the age group, Sp
meningitis mortality incidences were 2 to 12-fold greater than those for meningococcal meningitis. The lifetime
risks of pneumococcal meningitis disease and death were 0.6% (1 in 170) and 0.3% (1 in 304), respectively. The
incidences of these outcomes were highest among children age <1 year. However, the cumulative risk was highest
among persons age 5 to 59 years who experienced 59% of pneumococcal meningitis outcomes. After age 5 years
and depending on the country, 59-79% of meningitis cases were caused by serotype 1.
Conclusions: In the African meningitis belt, Sp is as important a cause of meningitis as Neisseria meningitidis,
particularly among older children and working age adults. The meningitis belt population needs an effective
serotype 1 containing vaccine and policy discussions should consider vaccine use outside of early childhood.
Background
Pneumococcal vaccine policy discussions for Africa have
focused almost exclusively on developing a pneumococ-
cal conjugate vaccine for use in infancy or early child-
hood [1,2]. The Global Alliance for Vaccines and
Immunization (GAVI)-sponsored PneumoADIP has a
mission statement limited to accelerating “access to
new, lifesaving pneumococcal vaccines for the world’s
children.” (website: http://www.preventpneumo.org/mis-
sion.cfm, last accessed June 24, 2008). Fewer discussions
have occurred regarding pneumococcal vaccine use
among older children and adults and no vaccine strate-
gies have been formulated. This focus on pediatric dis-
ease may be misplaced in the African meningitis belt
[3], a region of sub-Saharan Africa that is characterized
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any medium, provided the original work is properly cited.by particularly high and seasonal incidences of bacterial
meningitis and annual rainfall between 300 and 1100
mm. For example, data we collected from an exhaustive
polymerase chain reaction-based surveillance system in
and around Bobo-Dioulasso, Burkina Faso, during 2002-
7 suggest that high pneumococcal meningitis burden
extends throughout life and is associated with a high
case fatality ratio [4-6]. The current report aims to sum-
marize and model data on pneumococcal meningitis
burden in the African meningitis belt and to discuss
implications for vaccine policy.
Methods
Search criteria
We searched PubMed, CINAHL Plus, and the ISI Web
of Knowledge (containing SCI-Expanded, SSCI, and
A&HCI) databases and the references of retrieved arti-
cles. English and French language articles from 1970 to
the present were included. A single author (BDG) per-
formed all data abstraction and entered data into an
Excel spreadsheet. No validity assessment of retrieved
articles was performed.
Article retrieval
The primary meningitis outcome was the Sp meningitis
incidence by age group throughout life in the African
meningitis belt. Step one of the search was designed to
be sensitive in identifying potential articles. Conse-
quently, search terms were non-specific and included
“meningitis” in combination with one of the meningitis
belt countries including (alphabetically) Burkina Faso,
Chad, Ethiopia, The Gambia, Guinea, Guinea Bissau,
Mali, Niger, Senegal, and Sudan plus the northern half
of the Central African Republic, Cote d’Ivoire (and Ivory
Coast), Ghana, Kenya, Nigeria, Togo, and Uganda. Arti-
cles that reported only meningococcal, Haemophilus
influenzae type b (Hib), or epidemic meningitis in their
title had their abstracts reviewed but then uniformly
excluded as having no information on pneumococcal
disease. This led to identification of 45 articles, includ-
ing 12 from The Gambia, eight from Ethiopia, five each
from Northern Nigeria and Senegal, three each from
Mali, Niger and Burkina Faso, two from Cote d’Ivoire,
and one each from Chad, northern Ghana, northern
Togo, and northern Uganda.
Step two involved reviewing the retrieved articles to
identify those that reported age-specific pneumococcal
meningitis incidence throughout life. Only five articles
were identified that provided this information and thus
that were included in the evaluation [4,5,7-9]. Four of
these articles [4,5,8,9] were of approximately the same
quality in that they determined incidence by conducting
hospital and health center surveillance for cases and then
divided by the estimated population of the area from
which cases derived. In many settings in Africa, though,
population estimates may not be accurate. Consequently,
for these studies incidence rates should be considered
rough approximations. The fifth article from Ghana [7]
followed a defined population over time. All of the stu-
dies were used to estimate meningitis burden; the two
studies from Burkina Faso [4,5] reported overlapping
d a t af r o mt h es a m es u r v e i l l a n c es i t ea n ds o m eo ft h e
same time periods and thus data were combined. Each of
the articles reported surveillance that spanned all months
of the year. However, we could not exclude the possibility
that persons with meningitis symptoms were more likely
to present or receive an evaluation (i.e., lumbar puncture
and laboratory evaluation) during the epidemic meningi-
tis season months.
Each of the articles reported surveillance that spanned
all months of the year. However, we could not exclude
the possibility that persons with meningitis symptoms
were more likely to present to a health care facility and
receive an evaluation during the epidemic meningitis
season. This could have led to an underestimation of
pneumococcal meningitis incidence, including by sero-
type if some serotypes occurred preferentially during
particular seasons. This could have been assessed in part
by evaluating seasonality by age and serotype but none
of the studies reported this information. The similar
magnitude of increase of meningococcal and pneumo-
coccal meningitis during the meningitis season and the
known seasonality of meningococcal meningitis suggest
that this issue did not affect results to a large degree.
Model structure
Besides reporting the results from individual studies, we
estimated the lifetime risk of pneumococcal disease out-
comes. First, an average age-specific annual meningitis
incidence rate - weighted for the size of the population
under surveillance - was calculated for the four included
meningitis belt countries. Annual meningitis mortality
incidence rates were calculated as the weighted average
of the case fatality ratios multiplied by the annual
meningitis incidence rates within each age category. To
calculate lifetime meningitis risk, age-specific pneumo-
coccal meningitis and meningitis mortality incidence
rates were applied to a hypothetical population of
100,000 persons followed from birth until the 100
th
birthday (by which point all persons were assumed to
have died). Data are presented by age group through
age 99 years. Not all studies reported age groups at the
same level of detail; where data were missing, the inci-
dence rate for the closest available older age group was
used. Because data were sparse particularly for older
ages, for all outcomes identical values were used from
age 60 through 99 years. Ghana did not report age-spe-
cific case fatality ratios and thus was not included in
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dence rates. All estimates were adjusted for all-cause
mortality from all causes based on life tables for the
four study countries (website: http://www.who.int/who-
sis/database/life_tables/life_tables.cfm, last accessed July
2, 2008). This adjustment thus accounts for the rela-
tively low life expectancies found in the analyzed
countries.
The four study countries reported meningitis inci-
dence rates only among persons who presented to a
hospital or health center and who had a diagnostic
workup that led to documentation of meningitis. How-
ever, an unknown number of persons have undocumen-
ted meningitis because of failure to present,
pretreatment with antibiotics, lack of lumbar puncture,
or problems with specimen transport or storage. Anec-
dotal reports from our surveillance site in Burkina Faso
and our experience in Senegal, Mali, Togo, and Niger
suggest awareness of meningitis and care seeking are
relatively high, but the contribution of other factors
remains unknown. For example, during the dry epi-
demic meningitis season months, treatment may be pre-
sumptive based on clinical symptoms or documentation
of purulent cerebrospinal fluid without confirmation of
etiology. Manuscripts included in the current analysis
do not indicate any attempts by the study teams to
increase access to care or increase the percent of cases
with etiological confirmation (indeed, the Niger and
Senegal studies were retrospective). However, because
data from the meningitis belt on the effect of the factors
discussed above do not exist, we did not make an
attempt to model the burden of undocumented cases.
The African meningitis belt traditionally has been
considered to have abnormally high meningococcal -
but not necessarily pneumococcal - disease burden [3].
As a point of comparison, we present data on meningo-
coccal meningitis disease incidence and mortality rates.
Niger [8] and Senegal [9] reported these data in the
same manuscript while Burkina Faso reported data from
t h es a m et i m ep e r i o da n ds u r v e i l l a n c es i t ei nas e p a r a t e
manuscript [10]. Comparison data were not available for
Ghana.
Results
The four countries reporting meningitis incidence rates
throughout life included two major metropolitan areas
plus rural areas, involved in aggregate 36 years of fol-
low-up, spanned from 1970 to 2005, and identified
2,242 persons with pneumococcal meningitis (Table 1).
At all four sites, pneumococcal meningitis was seasonal
with the highest number of cases during the dry season
(i.e., the epidemic meningitis season). For three sites,
pneumococcal meningitis was highly seasonal with case
identification decreasing to near zero during other
months. Three studies reported serotype results and
among those at least 5 years of age (or 2 years for Sene-
gal) serotype 1 contributed at least 60% of cases for all
three sites (Table 2).
Table 1 Characteristics of evaluated countries
Characteristic Burkina Faso* Senegal* Niger* Ghana*
Surveillance design Prospective Retrospective Retrospective Prospective
Geographic extent Three districts Dakar Niamey Northern area
Surveillance population 880,000 950,000 550,000 140,000
Rural/Urban Both Urban Urban Rural
Study years 2002-2005 1970-1979 1981-1996 1998-2003
Microbiological methods Culture, antigen
detection, PCR
Culture Culture, antigen
detection
Culture, antigen
detection
Number of confirmed pneumococcal meningitis cases 249 983 934 76
Percent of cases occurring during dry/epidemic season
months of Dec-Apr
†
75% 49% 63% 69%
Two months with peak number of cases (percent of total)
† Jan-Feb (38%) Feb-Mar (21%) Feb-Mar (31%) Dec-Jan (35%)
Relation of pneumococcal to meningococcal seasonal peak Similar 2 months in
advance
1 month in advance 1 to 2 months in
advance
13-valent conjugate vaccine coverage of isolated serotypes
Age <5 years 67% 78% (age<2 yrs) No serotype data 100%
Age 5+ years 77% 94% (age 2+
yrs)
No serotype data 98%
Reference 4,5 9 8 7
* Human immunodeficiency virus prevalence in pregnant women age 15-24 years in capital city: Burkina Faso 2.3% (2002), Ghana 3.9% (2003), Senegal 1.1%
(2003). Adult HIV prevalence in Niger was 1.2% (2003). Website: http://www.unicef.org/publications/files/SOWC_2005_(English).pdf, last accessed October 2, 2008.
† In all studies cases per month were estimated from Figures as specific data were not presented.
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cal meningitis incidence rates were highest among
infants (Table 3). Children age 12 to 23 months also
may have been at increased risk but only one study
reported results specifically for this age group. Following
the first two years of life, and at all four study sites, age-
specific annual pneumococcal meningitis incidence were
consistent and high for all age groups, with weighted
means ranging from 6 to 14 per 100,000 per year.
Niger, Burkina Faso, and Senegal also reported - from
the same study site and period - data for meningitis due
to Neisseria meningitidis, the etiology typically asso-
ciated with the African meningitis belt; however, none
of the studies included data from years during which
major meningococcal meningitis epidemics occurred.
Compared to endemic meningococcal meningitis, pneu-
mococcal meningitis incidence rates were higher in
infancy, similar in early childhood, lower in later child-
hood, similar in young adulthood and then substantially
higher from age 30 years on. Pneumococcal case fatality
ratios were reported by age group for three sites and
were uniformly high, ranging from 36% to 66% (Table
4); the fourth country (Ghana) reported an overall
pneumococcal meningitis case fatality ratio of 44%.
Compared to meningococcal meningitis, pneumococcal
case fatality ratios were higher for all age groups and
annual mortality incidence rates were higher by a factor
of 2 to 18.
The overall estimated lifetime risk of laboratory-con-
firmed pneumococcal meningitis was 0.6% (1 in 170
persons) and for laboratory-confirmed pneumococcal
meningitis death was 0.3% (1 in 304 persons). Infants
age <1 year (i.e., the age group targeted by pneumococ-
cal conjugate vaccine childhood immunization pro-
grams) experienced 17% of cases and 16% of deaths,
while children age less than 5 years experienced 25% of
cases and 24% of deaths. Persons age 60 years or more
(i.e., one target age group for pneumococcal polysac-
charide vaccine) experienced 16% of cases and 19% of
deaths. By contrast, persons age 5 to 59 years of age,
Table 2 Serogroup/type distribution by age group and country
Serotype Burkina Faso Senegal Ghana
Age <
5 years
Age
5+ years
Age <
2 years
Age
2+ years
Age <
5 years
Age
5+ years
1 3 (17%) 18 (60%) 10 (9%) 90 (63%) 2 (33%) 51 (80%)
2 3 (17%) 15 (14%) 3 (2%)
3 6 (5%) 8 (6%) 2 (33%) 2 (3%)
5 3 (17%) 23 (21%) 8 (6%)
6A 5 (28%) 14 (13%)* 13 (9%)* 1 (2%)
6B 1 (6%)
7/7F 1 (3%) 1 (2%)
8 4 (6%)
9 6 (5%) 2 (1%)
10/10F 1 (6%) 1 (2%)
12A 1 (3%) 9 (8%)* 6 (4%)*
12B 1 (3%)
12F 2 (3%)
14 2 (7%) 5 (5%) 2 (1%) 2 (33%) 1 (2%)
18 4 (4%) 2 (1%)
19A 1 (3%) 4 (4%)* 4 (3%)*
19F 1 (3%)
21 1 (6%)
23 14 (13%) 5 (3%)
24A 1 (6%)
25A 2 (7%)
25F 2 (7%)
38 1 (2%)
NT 1 (3%)
Total 18 (100%) 30 (100%) 110 (100%) 143 6 (100%) 64 (100%)
* These cells present summary data on serogroups 6, 12, and 19 as serotype specific data were not available
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experienced 59% of cases and 57% of deaths.
The cumulative risk of pneumococcal meningitis and
meningitis death increased at a relatively constant rate
after age 5 years (Figure 1). The number of new cases
decreased among older persons despite a modest
increase in incidence rates because fewer and fewer peo-
p l er e m a i n e da l i v et oe x p e r i e n c eo u t c o m e s .T h et o t a l
number of outcomes was greatest during the first year
of life (Table 5). Nevertheless, the number of new cases
occurring during each age decade after 20 years was
comparable to that during infancy and up to three times
greater than that during the age category of 1-9 years.
Discussion
Meningitis
The current analysis showed that for at least the last 35
years, and based on approximately 35 years of surveil-
lance occurring in four countries, pneumococcal menin-
gitis in the meningitis belt has caused a high burden of
Table 3 Streptococcus pneumoniae (Sp) meningitis incidence rates (per 100,000 per year) by age group and country
[4,5,7-9]; Neisseria meningitidis meningitis incidences were available from Burkina Faso, Senegal, and Niger and
summary means are presented for comparison
Age (yrs) Burkina Faso Senegal Ghana* Niger* Mean
† for Sp Mean
† for Nm
‡
<1 77 95 42 150 98 24
1 to 4 14 17 19 10 14 20
5 to 9 13 4.5 25 6.4 9.1 19
10 to 14 10 3.7 6.9 7.8 17
15 to 19 11 2.4 20 9 7.8 11
20 to 29 6.1 4.0 4.7 5.8 5.0
30 to 39 14.1 5.2 18 3.2 8.6 3.3
40 to 49 19.1 7.8 7.9 12 2.8
50 to 59 8.0 11 9.7 3.3
60+ 8.1 15 25 10 2.8
*Not all studies reported age groups at the detail shown in column 1. The incidences in Ghana for persons age 5 to 19, 15 to 29, and 30 to 59 years and in Niger
for persons 40+ years were 25, 20, 18, and 7.9 per 100,000 persons per year, respectively.
†Weighted mean based on population under surveillance. Where data were not available from a study site for a specific age group, the next oldest age group
was used in the calculation of the weighted mean.
‡ Nm = Neisseria meningitidis. For comparison, data on Nm are presented for the same surveillance periods and sites except for Ghana, which did not report
these data.
Table 4 Streptococcus pneumoniae (Sp) meningitis case fatality ratios by age group and country [4,5,7-9]; Neisseria
meningitidis meningitis case fatality ratios were available from Burkina Faso, Senegal, and Niger and summary means
are presented for comparison
Age (yrs) Burkina Faso* Senegal Niger* Ghana* Mean
† Sp CFR
(mortality)
‡
Mean
† Nm
‡
CFR (mortality
§)
<1 52% 55% 58% 44% 53% (53) 12% (2.9)
1 to 4 50% 50% 57% 52% (7.4) 17% (3.3)
5 to 9 45% 48% 16% 36% (3.6) 10% (1.8)
10 to 14 50% 35% 43% (3.5) 10% (1.7)
15 to 19 44% 35% 62% 47% (3.5) 9% (1.0)
20 to 29 60% 58% 54% (3.1) 16% (0.8)
30 to 39 70% 20% 45% (4.2) 24% (0.8)
40 to 49 85% 60% 63% (7.9) 21% (0.6)
50 to 59 78% 61% (5.9) 43% (1.4)
60+ 93% 66% (6.7) 43% (1.2)
*Not all studies reported age groups at the detail shown in column 1. The CFRs in Burkina Faso for persons age 5 to 14 and 15+ years, in Niger for persons 40+
years, and in Ghana for all ages combined were 45%, 44%, 60%, and 44%, respectively.
†Weighted mean based on population under surveillance; Ghana was not included in the weighted means. Where data were not available from a study site for a
specific age group, the next oldest age group was used in the calculation of the weighted mean.
‡ Nm = Neisseria meningitidis. For comparison, data on Nm are presented for the same surveillance periods and sites except for Ghana, which did not report
these data.
§Mortality rate per 100,000 per year, based on the product of the meningitis incidence rate and the case fatality ratio.
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age adults, primarily during the epidemic meningitis sea-
son. Of the estimated 1 in 170 persons that will experi-
ence laboratory-confirmed pneumococcal meningitis,
many will develop sequelae such as hearing and vision
loss, seizure disorder, cerebral palsy, and mental retarda-
tion [11], although no specific data exist from the
meningitis belt on these sequelae among older children
and adults. Beyond laboratory-confirmed cases, an
unknown burden of unconfirmed cases exists, since
some persons do not present for care or receive a
lumbar puncture, others have received pretreatment
with antibiotics, and laboratory limitations may prevent
etiologic identification. This issue may be accentuated
for mortality, since lumbar punctures may be less likely
to be performed in critically ill and unstable patients.
Consequently, data presented very here should be con-
sidered minimum estimates.
Within the limits of our analysis, pneumococcal
meningitis burden among older children and working
age adults may surpass that for diseases currently tar-
geted for routine immunization in meningitis belt coun-
tries. For example, WHO has recommended universal
infant Hib vaccination [12], and the meningitis belt in
particular has among the world’s highest annual inci-
dence rates at 34-60 per 100,000 children aged under 5
years [13]. Almost the entire risk of Hib disease, though,
occurs during childhood. By contrast, the high pneumo-
coccal meningitis incidences that occur throughout life
result in a higher pneumococcal meningitis risk during
ages 5 to 49 years than Hib meningitis during child-
hood. Beyond the higher cumulative risk of pneumococ-
cal outcomes, disease, disability, and death among
working adults may impoverish entire families or
extended families, triggering a cascade of adverse health
events [14].
Compared to the United States and Europe, where a
bimodal meningitis age distribution with peaks in
infants and the elderly is observed, pneumococcal
meningitis epidemiology in the meningitis belt appears
distinctly different, with strong seasonality, predomi-
nance of serotype 1 outside of childhood, higher inci-
dences, higher case fatality ratios, and an age
distribution with a concentration on older children and
working age adults [15-19]. Indigenous persons of North
Figure 1 Cumulative Streptococcus pneumoniae meningitis and meningitis death cases. Among a hypothetical population of 100,000
persons living in the meningitis belt and followed from birth to death, the cumulative number of Streptococcus pneumoniae meningitis and
meningitis death cases occurring by 5-year age increments.
Table 5 Estimates of laboratory-confirmed Streptococcus
pneumoniae (Sp) meningitis cases and deaths within age
groups
Age group in years Meningitis cases Meningitis deaths
<1 98 53
1 to 4 52 27
5 to 9 37 15
10 to 14 32 14
15 to 19 31 14
20 to 29 45 24
30 to 39 64 31
40 to 49 83 53
50 to 59 56 34
60 to 69 47 32
70 to 79 30 20
80 to 89 10 7
90 to 99 2 1
Total 587 326
These estimates were made for a hypothetical population of 100,000 persons
in the African meningitis belt followed from birth through age 99 years
[4,5,7-9].
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ease incidences that are among the world’sh i g h e s t .
However, Sp meningitis incidence in these populations
is still relatively low compared to incidence rates
observed in the African meningitis belt, and other
aspects of Sp epidemiology are similar to what is seen in
developed country populations [16,20,21]. African coun-
tries outside the meningitis belt have, not reported
population-based pneumococcal meningitis data across
the entire life span. An unpublished study from Kenya
[22] reported annual incidence rates among adults for
all invasive pneumococcal disease - including bactere-
mia, which can cause 10-20 fold more invasive disease
than meningitis [15] - of 261 and 3.3 per 100,000
among, respectively, persons with and without con-
firmed human immunodeficiency virus (HIV) infection.
The latter rate for all invasive disease is substantially
lower than the Sp meningitis incidence seen in the
meningitis belt. North-central Uganda, which borders
the meningitis belt, reported an annual pneumococcal
meningitis incidence among children under age 5 years
of 28 to 42 per 100,000 versus 3 to 20 per 100,000
reported in tropical Kampala [23]. These data suggest
that the meningitis belt has a unique pneumococcal dis-
ease epidemiology even within Africa.
T h em e c h a n i s m sr e s p o n s i b l ef o rt h eS pe p i d e m i o l o g y
found in the meningitis belt remain unknown. The
observed seasonal pattern indicates some overlap in risk
factors with meningococcal meningitis [24] including
climatic conditions, concurrent respiratory infections,
decreased host immunity and others. Although HIV
plays an important role in many African countries [22],
meningitis belt countries have relatively low HIV preva-
lences and the epidemiology of pneumococcal meningi-
tis in the region has been relatively stable since the
1970s when HIV was presumably of little importance. It
is unlikely that circulation and transmission of serotype
1 alone explains the observed patterns since Asia, with
the world’s lowest documented pneumococcal meningi-
tis incidences, reports serotype 1 as the most common
cause of meningitis in all age groups [25]. Lastly, menin-
gitis belt countries have a high prevalence of hemoglobi-
nopathies mainly due to hemoglobin S and C [26], and
these greatly increase the risk of invasive pneumococcal
disease [27]. High hemoglobinopathy prevalence, how-
ever, is not unique to the meningitis belt.
Implications for pneumococcal pneumonia
The African meningitis belt, home to about 350 million
people, is characterized by an extraordinarily high inci-
dence of acute bacterial meningitis, occurring mainly
during the dry season. No data, however, exist from the
meningitis belt on age specific pneumonia incidence,
either overall or specifically for pneumococcus. Thus, it
remains unknown if the high pneumococcal meningitis
disease burden occurs in association with a high pneu-
mococcal pneumonia burden. In industrialized coun-
tries, numerous studies have estimated the ratio of
bacteremic pneumococcal pneumonia to meningitis
[15-21,28,29]. Examination of data from these studies
(Additional file 1, Table S1) illustrates that this ratio
remains relatively stable across populations (including
high incidence populations such as Alaska Native peo-
ple) and increases sharply with age. If ratios seen in
developed countries hold true for meningitis belt coun-
tries, it would imply a very high risk of pneumococcal
pneumonia (estimated as 1 in every 15 persons using
the presented meningitis data) and overall pneumococ-
cal mortality (estimated as 1 in every 62 persons) with a
risk even more weighted toward ages outside of early
childhood than that seen for meningitis.
The applicability of this ratio for meningitis belt popu-
lations, however, is unknown. The only relevant current
data point from in or near the meningitis belt is the
pneumococcal conjugate vaccine trial (using a serotype
1 containing vaccine) from The Gambia, located just
outside the Western edge of the meningitis belt [30].
Based on reported vaccine-preventable disease inci-
dences for various outcomes, the ratio of vaccine-pre-
ventable pneumococcal pneumonia (bacteremic and
non-bacteremic) to meningitis was 30 to 1 and the ratio
of all pneumococcal mortality to pneumococcal menin-
gitis mortality was 8.8 to 1. These figures would imply
an even higher risk of Sp pneumonia and mortality than
the values reported in the previous paragraph. The
Gambia trial, though, is limited by its location outside
of the meningitis belt and a study population limited to
children age 6 weeks to 2 years. In summary, there is a
need for data on pneumococcal pneumonia across age
groups specifically for the meningitis belt.
Limitations
Our study had at least six limitations. Data were not
available from countries located in the eastern part of
the meningitis belt such as Sudan and Ethiopia, where
pneumococcal disease epidemiology in theory may be
different. Meningitis incidence estimates from Niger,
Burkina Faso, and Senegal were based on dividing case
counts by the population data available, which may be
imprecise and therefore overestimate or underestimate
true incidence rates. We did not find data on the pro-
portion of all persons with pneumococcal meningitis
that present for definitive diagnosis either overall or by
syndrome or age group. Although serotype 1 appears to
have predominated over many years in the meningitis
belt, serotype distributioni sad y n a m i cp r o c e s s .O u r
results are valid for a situation with predominance of
serotype 1 in older children and adults and may require
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Senegal provided mortality data restricted to elderly per-
sons and thus estimates for this group are uncertain.
Lastly, a quality assessment of the studies was not con-
ducted and approximations in denominators and inclu-
sion of different time periods could have affected results.
Implications for vaccine use in the meningitis belt
Existing data indicate that meningitis belt populations
need a serotype 1-containing vaccine. The licensed 7-
valent pneumococcal conjugate vaccine does not contain
serotype 1, may be associated with increases in non-vac-
cine serotypes [31-34], and thus likely will have little
role outside of early childhood in the meningitis belt.
Existing 23-valent polysaccharide vaccines could have a
role, but these vaccines do not reduce carriage, may be
no less expensive than conjugate vaccines, and manufac-
turers may have little interest in increasing production.
Before or concurrent with introduction, the effectiveness
of serotype 1 containing vaccine must be confirmed. In
The Gambian trial, vaccine was not effective against ser-
otype 1 disease, however the results were based on a
total of only six invasive isolates [35]. Other studies -
including in The Gambia - have documented robust
immunologic response against serotype 1 [35-38] as well
as vaccine effectiveness with conjugate [39] or polysac-
charide vaccines [40]. The latter finding is encouraging
since conjugate vaccines usually elicit more robust
immune responses, including for serotype 1 and outside
of childhood [41,42]. Nevertheless, questions about sero-
type 1 conjugate vaccine effectiveness must be resolved
before widespread vaccine implementation.
A policy of universal infant pneumococcal vaccination
may provide indirect protection to older persons if
ongoing Sp carriage and transmission requires young
children [43]. If transmission for some serotypes can be
maintained solely among older persons, though, infant
vaccination will have little impact on the pneumococcal
disease burden we describe here. Data on serotype 1
transmission dynamics, including the contribution of
different age groups, are lacking in the meningitis belt.
Among African populations outside of the meningitis
belt, serotype 1 carriage is rarely seen [44-46] but this
may indicate a short carriage duration rather than infre-
quent transmission. During a serogroup A meningococ-
c a le p i d e m i ci nB u r k i n aF a s o ,w ef o u n da m o n ga
representative community-based population sample of
persons aged 1 to 39 years relatively flat age distribu-
tions of overall pneumococcal carriage as well as IgG
seroprevalence for serotype 1 similar to other serotypes.
Moreover two of three serotype 1 carriage isolates were
identified from persons aged greater than 5 years [6].
Most logistical issues associated with delivering pneu-
mococcal vaccine outside of infancy have already been
addressed during planning by the GAVI Alliance, WHO,
and Unicef for preventive conjugate meningococcal ser-
ogroup A vaccine introduction and for the current yel-
low fever vaccine campaigns in sub-Saharan Africa. For
example, one proposed plan for the meningococcal vac-
cine is to conduct an initial mass vaccination campaign
among persons 1 to 29 years of age, followed by contin-
uous routine infant vaccination. Similar mass vaccina-
tion campaigns with pneumococcal conjugate vaccine
likely would have an immediate and high impact on
pneumococcal disease in the region, and possibly higher
than that associated with routine infant immunization.
Because of longer antibody persistence among indivi-
duals older than 1 year, a single dose among persons 1
to 29 years of age probably would have a long-term
impact on pneumococcal disease burden. Mass cam-
paigns and routine infant immunization could occur
simultaneously, although costs, vaccine availability, and
programmatic issues may require a sequential approach.
Efforts also should be made to improve and document
high vaccination coverage.
Conclusions
Based on available data for pneumococcal disease epide-
miology in the African meningitis belt, policymakers
should consider mass vaccination campaigns among older
children and adults to precede or accompany routine
infant immunization. To guide policy decisions, there
remains a substantial need for data on serotype-specific
pneumococcal transmission patterns, pneumococcal pneu-
monia and invasive disease burden across age strata, and
pneumonia and meningitis sequelae. A vaccine demon-
stration project [47] measuring impact on meningitis and
pneumonia outcomes could provide this information as
well as information on serotype-specific vaccine effective-
ness, vaccine impact on meningitis, pneumonia, and car-
riage, and assessment of programmatic, logistic, and
economic issues associated with vaccine introduction.
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